Mexico Atopic Dermatitis Therapeutics Market Report 2022 to 2030

Mexico Atopic Dermatitis Therapeutics Market Analysis

$ 3999

The Mexico Atopic Dermatitis Therapeutics Market was valued at US $185 Mn in 2022, and is predicted to grow at (CAGR) of 9.05% from 2023 to 2030, to US $369 Mn by 2030. The key drivers of this industry include the upward trend in prevalence of Atopic Dermatitis (AD), supportive government policies and shifting treatment preferences. The industry is primarily dominated by players such as Sanofi, AbbVie, Pfizer, Bayer, GlaxoSmithKline, Merck among others.

ID: IN10MXPH435 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico

Buy Now

Mexico Atopic Dermatitis Therapeutics Market Analysis: Executive Summary

The Mexico Atopic Dermatitis Therapeutics Market is at around US $185 Mn in 2022 and is projected to reach US $369 Mn in 2030, exhibiting a CAGR of 9.05% during the forecast period.

Atopic dermatitis (AD), often known as eczema, is a chronic inflammatory skin illness characterized by redness, itching, and inflammation. It frequently develops in isolated patches on various body parts and can be aggravated by factors such as dry skin, stress, and exposure to specific irritants or allergens. The most noticeable symptoms are extreme itching, redness, dryness, and the formation of tiny, fluid-filled blisters that may leak fluid and create crusts. Emollients are commonly used to moisturize the skin, topical corticosteroids to reduce inflammation, and, in extreme situations, systemic immunosuppressants. Several pharmaceutical firms manufacture treatments for atopic dermatitis, including Regeneron Pharmaceuticals and Sanofi's Dupixent (Dupilumab), Pfizer's Eucrisa (Crisaborole), and Novartis' Elidel (Pimecrolimus).

The overall prevalence of AD is estimated to be around 7.4% for the adult population and around 8–15% for children in Brazil. The market is being driven by significant factors such as the rising prevalence of AD, an improved healthcare system, and the changing lifestyle of the population. However, conditions such as high treatment costs and a lack of human resources limit the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Rising prevalence of AD: The estimated prevalence of atopic dermatitis is around 7.4% among adults and ranges from approximately 8.2% to 15.1% among children in Mexico. The expanding population affected by AD results in heightened demand for effective treatments, thereby driving market demand.

Improved healthcare system: The expansion of healthcare infrastructure and insurance coverage, coupled with increased public awareness about AD through initiatives such as the Atopic Dermatitis Quality of Care, motivates patients to actively pursue diagnosis and treatment, thereby enhancing market demand.

Changing lifestyle: With the increasing urbanization of Mexico, there is a potential rise in the risk of atopic dermatitis (AD) due to elevated exposure to environmental pollutants and allergens associated with urban living. This factor contributes to the continued growth of the market.

Market Restraints

Lack of human resources: Disparities in healthcare access based on geography can create challenges for individuals in rural areas or with lower socioeconomic backgrounds in obtaining accurate diagnosis and treatment. The unequal distribution of dermatologists, particularly in rural areas, creates obstacles to accessing diagnosis and proper treatment.

High cost of treatment: The substantial expense associated with specific medications, particularly newer biological therapies, can pose a considerable challenge for patients, particularly those lacking sufficient insurance coverage. The dependence on imported medications adds to the costs, as potential import duties and currency fluctuations contribute to the overall financial burden.

Healthcare Policies and Regulatory Landscape

In Mexico, the regulatory landscape for health and pharmaceuticals is overseen by the Federal Commission for the Protection against Sanitary Risks (Comisión Federal para la Protección contra Riesgos Sanitarios, or COFEPRIS). COFEPRIS operates under the Ministry of Health and plays a pivotal role in regulating and supervising health products, including pharmaceuticals, medical devices, and healthcare services. It is responsible for ensuring that these products meet safety, efficacy, and quality standards before they are made available to the public. COFEPRIS works closely with other regulatory bodies and international organizations to align Mexico's health standards with global best practices.

The process of obtaining a license or drug approval in Mexico involves submitting a comprehensive application to COFEPRIS. The application typically includes detailed information about the product, its manufacturing processes, clinical trial data (if applicable), and compliance with relevant regulations. COFEPRIS conducts a thorough review of the submission, assessing the safety, efficacy, and quality of the product. If the product meets the required standards, COFEPRIS grants the necessary approvals and licenses. This regulatory process is essential for ensuring the safety and effectiveness of healthcare products in Mexico and aligning with international regulatory standards.

Competitive Landscape

Key Players

Sanofi
Novartis
GlaxoSmithKline
Bayer
Galderma
AbbVie
Johnson and Johnson
AstraZeneca
Ache Laboratories
Genomma Lab International

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Mexico Atopic Dermatitis Therapeutics Market Segmentation

By Drug Class

Corticosteroids
Calcineurin Inhibitors
Immunosuppressants
Biologic Therapy
PDE-4 Inhibitor
Antibiotics
Antihistamines
Emollients

By Route of Administration

Topic
Oral
Injectable

By Severity type

Mild
Moderate
Severe

By Age Group

18 years and below
19 years and above

By Distribution channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Dermatology Clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.